Post-Transplantation Anemia and Risk of Death Following Lung Transplantation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 963 KB, PDF-dokument

Background: Post-transplantation anemia (PTA) is frequent among solid organ transplant recipients and has been associated with increased morbidity and mortality. However, the prevalence and impact of PTA in lung transplant recipients is still not elucidated. Methods: We performed a retrospective cohort study of adult Danish lung transplant recipients between January 2010 and December 2019. The prevalence and severity of PTA were determined during the first three years post-transplantation. Associations between PTA and selected risk factors were established using uni- and multivariate logistic regression models. Results: A total of 278 patients were included. At one and three years post–lung transplantation the prevalence of PTA was 75% and 52%, respectively. Male sex was associated with increased odds of PTA at all time points (aOR ranging from 2.3, 95% CI 1.1-4.6, P = 0.02 to 5.9, 95% CI 2.6-14, P < .001). Cystic fibrosis was also associated with anemia at one-year post-transplantation (aOR 4.3, 95% CI 1.2-17, P = 0.03). We found no strong associations between PTA and renal function or viral infections. Excess mortality in recipients with moderate or severe anemia compared to patients with mild or no anemia was borderline statistically significant at one-year post-lung transplantation (aHR 2.0, 95% CI 0.9-4.4, P = 0.07). Discussion: Post-transplantation anemia is very common in Danish lung transplant recipients. Male sex and cystic fibrosis are independent risk factors for development of anemia. Further investigation on PTA, the underlying mechanisms, and its clinical impact is needed.

OriginalsprogEngelsk
TidsskriftTransplantation Proceedings
Vol/bind54
Udgave nummer8
Sider (fra-til)2329-2336
Antal sider8
ISSN0041-1345
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
TKL received grants from Astellas and The Heart Centers Research Committee (Rigshospitalet) and personal fees from Boehringer Ingelheim, AMBU, and AstraZeneca. OR received a grant from The Research Foundation of Rigshospitalet, and a grant from A.P. Moeller Fonden. MP received a grant from Roche, non-financial support from Boehringer Ingelheim, personal fees from Mallinckrodt, Novartis, GlaxoSmithKline, and AstraZeneca. MH received unrestricted grants from The Helen and Ejnar Bjoernow Foundation, The Lundbeck Foundation grant R187-2015-2148 and Skibsreder Per Henriksen, R. og Hustrus Fond and Rigshospitalet Research Council. SDN received unrestricted and restricted research grants from Novo Nordic Foundation and Rigshospitalet Research Council. All grants and fees not related to this work. CGC, TBB, HHS, KJ and PB have no conflict of interest to disclose. This study was financially supported by The Clinical Research Unit, Heart Centre, Rigshospitalet. The study was supported by PERSIMUNE (grant number DNRF126).

Publisher Copyright:
© 2022 The Authors

ID: 338362100